Although rhTPO has shown remarkable efficacy in mitigating grade 3/4 thrombocytopenia and accelerating platelet recovery to >100 × 109/L (Mei et al., 2021; Yu et al., 2021), its similarity to endogenous TPO may lead to antibody development, potentially limiting its clinical use. This evidence concerns the gene TPO and Thrombocytopenia.